The Era of Immunotherapy
in Earlier Stages of Non-Small Cell Lung Cancer
(NSCLC): What Managed Care Needs to Know for
Improved Clinical and Economic Outcomes
A continuing medical
education activity sponsored by NAMCP and AAMCN
This webinar series will provide critical updates on the advances in
the management of NSCLC, including
how to translate the most recent data into clinical and
These are archives of live webinars held between February 18 to
February 27, 2020.
If you participated in any of the live webinars, you are not
to claim credit from the archive of that webinar.
By clicking on each of the titles, you will be able to participate
in each part.
It is not required that you participate in all three or in order.
Each session has its own specific valid dates
This series is supported by educational
AstraZeneca and Merck & Co.
This activity is intended for healthcare professionals practicing in managed
Instructions for CME/CNE: Complete the pre-test,
listen to the audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your internet
browser without completing the post test, you will have ONE more opportunity to
complete. A score of 70% must be achieved on the post test to receive continuing
education credits. If you do not pass the post test after two attempts, you will
not be eligible to try again. Once you complete the evaluation form and score
70% or higher on your post test, you will automatically be given your
Lung cancer is the worldwide leading cause of
cancer-related mortality. The vast majority of these cases (about 85%) are
characterized as non-small cell lung cancer (NSCLC). In recent years, NSCLC has
been found to have a multidimensional typology and etiology driven by molecular
changes in lung tissue. The knowledge that the molecular structure of tumor
cells has been altered has led to the development of novel checkpoint inhibitors
(ICI). It was only recently that ICIs have approved for treating patients with
stage III disease following concurrent chemoradiation therapy, the aim of which
is to prevent disease progression.
This live webinar series on stage three and earlier NSCLC will provide attendees
with critical updates on the advances in ICIs, including how to translate the
most recent data into clinical and administrative practice.